Subject(s)
Cardiac Valve Annuloplasty , Extracellular Matrix/transplantation , Heart Valve Diseases/surgery , Heart Valves , Postoperative Complications , Cardiac Valve Annuloplasty/instrumentation , Cardiac Valve Annuloplasty/methods , Child , Child Development , Echocardiography , Heart Valves/growth & development , Heart Valves/surgery , Humans , Monitoring, Physiologic/methods , Postoperative Complications/etiology , Postoperative Complications/prevention & control , Time , Transplantation, HeterologousABSTRACT
Congenital heart diseases are corrected early in life, so the surgical procedure has to maintain the maximum potential for growth. The quest for the ideal material for cardiac tissue repair is still ongoing. Here, we describe our preliminary experience with an extracellular matrix for cardiac and vascular tissue repair. Between August 2009 and April 2011, 26 patients underwent cardiac surgery using the CorMatrix patch for vascular repair (10 pulmonary artery, four ascending aorta, three aortic arch and one right ventricular outflow tract) or for valve reconstruction (five aortic, two tricuspid, one mitral and one pulmonary valve); in four cases, the repair was associated with pericardial closure using the same patch. There were no deaths, and at a mean follow-up of 13.2 months, there was no evidence of patch-related complications either in the vascular position or when used for valve repair. The ideal material for cardiac tissue repair should be haemostatic and resistant to tearing and calcification, and possibly one that will not induce an inflammatory cascade. In the last 25 months, we used an extracellular matrix for cardiac and vascular tissue repair. The patch is advocated to induce the patient's own tissue regeneration. The early results are encouraging, but a longer follow-up is needed to understand the real potential of this material.
